- Home
- PETS vs BNTC Comparison
PETS vs BNTC Comparison
Compare PETS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | BNTC |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 405.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PETS | BNTC |
|---|---|---|
| Price | $3.90 | $12.45 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.20 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 6.9M | 235.3K |
| Earning Date | 02-02-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $9.70 |
| 52 Week High | $6.08 | $17.15 |
Technical Indicators
Market Signals| Indicator | PETS | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 43.39 |
| Support Level | $1.69 | $12.78 |
| Resistance Level | $4.05 | $13.68 |
| Average True Range (ATR) | 0.34 | 0.80 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 92.49 | 42.06 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.